Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.44 |
| ▸ | ABAT | P80404 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84104 | 0.80 | IDO1 (0.58) | HRH3LOXL2ABATCSNK2A1SLC6A2 | |
| SCHEMBL2865480 | 0.79 | ADRB2 (0.41) | TSHRMAPK1ATMTDP1L3MBTL1 | |
| SCHEMBL4574471 | 0.78 | TSHR (0.41) | TSHRMAPK1ATMTDP1L3MBTL1 | |
| SCHEMBL8750481 | 0.78 | TSHR (0.64) | TSHRMAPK1ATMTDP1L3MBTL1 | |
| SCHEMBL13189390 | 0.78 | ADRB2 (0.52) | HRH3LOXL2ABATSLC6A2SLC6A3 | |
| SCHEMBL7677443 | 0.76 | ABAT (0.48) | HRH3LOXL2ABATSLC6A2TAAR1 | |
| SCHEMBL2406237 | 0.76 | PTGS1 (0.53) | TSHR | |
| SCHEMBL2778066 | 0.76 | ABAT (0.48) | HRH3LOXL2ABATSLC6A2TAAR1 | |
| SCHEMBL23040222 | 0.76 | TSHR (0.40) | TSHRMAPK1ATMTDP1L3MBTL1 | |
| SCHEMBL7372727 | 0.76 | ABAT (0.48) | HRH3LOXL2ABATSLC6A2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-02-21 | — | — | US | disclosed |
| WO-2021041588-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2021-03-04 | — | — | US | disclosed |
| CN-109809962-A | A kind of new synthetic method of 2- (4- bromomethyl) phenylpropionic acid | 盘锦格林凯默科技有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-101412670-B | Method for synthesizing loxoprofen sodium | ZHEJIANG APELOA PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD | 2011-11-09 | — | — | CN | disclosed |
| CN-101412670-A | Method for synthesizing loxoprofen sodium | ZHEJIANG PULUO PHARMACEUTICAL (CN) | 2009-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | DGKZ, DGKA, DGKG | HRH3 1038/4885LOXL2 3987/4885ABAT 4180/4885 |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | HRH3 1038/4885LOXL2 3987/4885ABAT 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.